A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis

Neurology

Volumn 51, Issue 2, 1998, Pages 583-586

  Borasio, Gian Domenico ^e   Robberecht, W ^f   Leigh, P N ^f   Emile, J ^b   Guiloff, R J ^c   Jerusalem, F ^f   Silani, V ^f   Vos, P E ^a   Wokke, J H J ^f   Dobbins, T ^d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b University Medical Center   (France)

^c CHARING CROSS HOSPITAL   (United Kingdom)

^d CEPHALON INC   (United States)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT SOMATOMEDIN C;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0031722582     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.2.583     Document Type: Article

References (10)

1. Lewis ME, Neff NT, Contreras PC, et al. Insulin-like growth factor-I: potential for treatment of motor neuronal disorder. Exp Neurol 1993;124:73-88.
2. Festoff BW, Yang SX, Stong D. Strategies for the use of recombinant human growth hormone and insulin-like growth factor I in amyotrophic lateral sclerosis. In: Blackman MR, Harman SM, Roth J, Shapiro JR, eds. Growth hormone releasing hormone, growth hormone and IGF-I: basic and clinical advances. New York: Springer; 1995:110-128.
3. Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor I (rhIGF-I) on the progression of amyotrophic lateral sclerosis. A placebo-controlled study. Neurology 1997;49:1621-1630.
4. Appel V, Stewart SS, Smith G, Appel SH. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 1987;22:328-333.
5. Bergner M, Bobbit RA, Carter WB, Gilson BS. The sickness impact profile: development and final revision of a health status measure. Med Care 1981;19:787-805.
6. Contreras PC, Steffler C, Yu E, Callison K, Stong D, Vaught JL. Systemic administration of rhIGF-I enhanced regeneration after sciatic nerve crush in mice. J Pharmacol Exp Ther 1995;274:1443-1449.
7. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population: validation of a scoring system and a model for survival prediction. Brain 1995;118:707-719.
8. Lotz B, Brooks B, Sanjak M, et al. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996;46:1244-1249.
9. Miller RG, Petajan JH, Bryan WW, et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. Ann Neurol 1996;39: 256-260.
10. Froesch ER, Hussain MA, Schmid C, Zapf J. Insulin-like growth factor I: physiology, metabolic effects and clinical use. Diabetes Metab Rev 1996;12:195-215.